Page last updated: 2024-12-10
poliothrysoside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
poliothrysoside: isolated from Laxocalyx urticifolius; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3084295 |
| CHEMBL ID | 512419 |
| MeSH ID | M0454868 |
Synonyms (15)
| Synonym |
|---|
| beta-d-glucopyranoside, 4-hydroxy-2-(hydroxymethyl)phenyl, 6-benzoate |
| xylosmoside |
| glucopyranoside, alpha,4-dihydroxy-o-tolyl, 6-benzoate |
| 18463-25-7 |
| poliothrysoside |
| poliothyrsoside |
| CHEMBL512419 |
| tributyltinchloroacetate |
| ncgc00385097-01_c20h22o9_beta-d-glucopyranoside, 4-hydroxy-2-(hydroxymethyl)phenyl, 6-benzoate |
| NCGC00385097-01 |
| AKOS032948709 |
| ((2r,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(4-hydroxy-2-(hydroxymethyl)phenoxy)tetrahydro-2h-pyran-2-yl)methyl benzoate |
| DTXSID10939852 |
| 4-hydroxy-2-(hydroxymethyl)phenyl 6-o-benzoylhexopyranoside |
| FS-10508 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID722960 | Antimalarial activity against Plasmodium yoelii infected in Swiss mouse assessed as inhibition of beta-hematin formation in plasma after 16 hrs by spectrophotometric analysis | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Isolation and identification of β-hematin inhibitors from Flacourtia indica as promising antiplasmodial agents. |
| AID1163840 | Induction of [3H] 2-deoxyglucose uptake in chronic insulin resistant mouse 3T3L1 cells assessed as maximum uptake at 10 uM by liquid scintillation counting | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Poliothrysoside and its derivatives as novel insulin sensitizers potentially driving AMPK activation and inhibiting adipogenesis. |
| AID385238 | Inhibition of COX2 at 10 uM | 2008 | Journal of natural products, May, Volume: 71, Issue:5 | Itosides J-N from Itoa orientalis and structure - anti-COX-2 activity relationship of phenolic glycosides. |
| AID722963 | Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Isolation and identification of β-hematin inhibitors from Flacourtia indica as promising antiplasmodial agents. |
| AID722961 | Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Plasmodium falciparum 3D7 | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Isolation and identification of β-hematin inhibitors from Flacourtia indica as promising antiplasmodial agents. |
| AID663478 | Inhibition of Dengue virus NS5 polymerase assessed as inhibition of radiolabeled guanosine incorporation into homopolymeric cytosine RNA template by liquid scintillation counting | 2012 | Journal of natural products, Apr-27, Volume: 75, Issue:4 | Flacourtosides A-F, phenolic glycosides isolated from Flacourtia ramontchi. |
| AID722964 | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 72 hrs by SYBR green assay | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Isolation and identification of β-hematin inhibitors from Flacourtia indica as promising antiplasmodial agents. |
| AID722962 | Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay | 2013 | European journal of medicinal chemistry, Feb, Volume: 60 | Isolation and identification of β-hematin inhibitors from Flacourtia indica as promising antiplasmodial agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||